Immunic is a biotechnology company developing oral drugs for multiple sclerosis and gastrointestinal diseases. It last closed at $7.33 on Nov 17, up 1.38% on the day.
Only 1 firm rated IMUX in the past 90 days, not enough for a consensus
Average 12-month target
$45.00
▲ 513.9% upside
Based on 1 analyst who set a price target on IMUX in the past 90 days. The average target is $45.00, with a high of $45.00 and a low of $45.00, compared with the last close of $7.33.
Low $45.00Avg $45.00High $45.00
Blue marker: last close $7.33
Highest target$45.00
Average target$45.00
Lowest target$45.00
Latest rating changes
WedbushReiterated
Sep 10Buy$45
WedbushInitiated
Aug 17Buy$45
B. Riley SecuritiesMaintained
May 22Buy$27
StifelInitiated
Apr 17Buy$2.50
Date
Firm
Action
Rating
Price target
Sep 10
Wedbush
Reiterated
Buy
$45
Aug 17
Wedbush
Initiated
Buy
$45
May 22
B. Riley Securities
Maintained
Buy
$27
Apr 17
Stifel
Initiated
Buy
$2.50
Loading…
Technical Analysis
IMUX · as of the Nov 17 close · updated after every close
Downtrend
The stock is 4% below its 20 day and 16% below its 50 day average. It is 58% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 42). The nearest support is the Pivot at $7.30, and the nearest resistance the Pivot R1 at $7.52.
Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 7.9%/day
Key levels
$17.4352 week high+137.8%
$11.70100 day average+59.6%
$11.57200 day average+57.8%
$8.4750 day average+15.6%
$8.22Swing high (Oct 29)+12.1%
$7.6120 day average+3.8%
$7.52Pivot R1+2.6%
$7.33Last close
$7.30Pivot−0.4%
$7.16Swing low (Nov 2)−2.3%
$7.12Pivot S1−2.9%
$5.0652 week low−31.0%
Indicators
RSI (14)
41.89
Middle of its range
Neutral
MACD
-0.27
Above its signal line
Bullish
Stochastic
17.8
Near the bottom of its range
Oversold
ADX (14)
16.9
No clear trend
Williams %R
-81.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-107.1
Oversold below −100, overbought above 100
Oversold
Rate of change
−3.5%
Change over 10 sessions
Bearish
ATR (14)
$0.58
Typical daily range, 7.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 24.1%/day
Key levels
$17.4352 week high+137.8%
$11.70100 day average+59.6%
$11.57200 day average+57.8%
$8.4750 day average+15.6%
$8.22Swing high (Oct 29)+12.1%
$7.6120 day average+3.8%
$7.52Pivot R1+2.6%
$7.33Last close
$7.30Pivot−0.4%
$7.16Swing low (Nov 2)−2.3%
$7.12Pivot S1−2.9%
$5.0652 week low−31.0%
Indicators
RSI (14)
35.36
Weak, oversold below 30
Neutral
MACD
-1.35
Below its signal line
Bearish
Stochastic
10.7
Near the bottom of its range
Oversold
ADX (14)
28.1
Trending down
Williams %R
-91.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-83.8
Oversold below −100, overbought above 100
Neutral
Rate of change
−35.8%
Change over 10 sessions
Bearish
ATR (14)
$1.77
Typical daily range, 24.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for IMUX
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how IMUX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow IMUX usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How IMUX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IMUX is in one of them and how their past IMUX trades turned out.
Immunic is a biotechnology company that develops oral drugs for neurologic and gastrointestinal diseases. Its lead candidate, vidofludimus calcium, is in Phase 3 testing for relapsing multiple sclerosis, and its IMU-856 candidate is being developed for conditions such as celiac disease and inflammatory bowel disease. The company has no products approved for sale yet and has not generated revenue from product sales. It is headquartered in New York, with its main research operations in Germany.